HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

(2021) Robert Jenke et al.   Cancers

Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

(2020) Eugenio Cavalli et al.   MOLECULES

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer

(2020) Bin Liu et al.   BIOCHEMICAL PHARMACOLOGY

Two-hit wonders: The expanding universe of multitargeting epigenetic agents

(2020) Angel R. de Lera et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

(2020) Terence C. S. Ho et al.   JOURNAL OF MEDICINAL CHEMISTRY

7-Hydroxycoumarins Are Affinity-Based Fluorescent Probes for Competitive Binding Studies of Macrophage Migration Inhibitory Factor

(2020) Zhangping Xiao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

(2020) Joshua P. Smalley et al.   MOLECULES

MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential

(2019) Justin C. Penticuff et al.   Nature Reviews Urology

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms

(2019) Junting Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor

(2019) Bin Liu et al.   Cancers

Structure-activity relationships for binding of 4-substituted triazole-phenols to macrophage migration inhibitory factor (MIF)

(2019) Zhangping Xiao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Dual or multi-targeting inhibitors: The next generation anticancer agents

(2018) Nulgumnalli Manjunathaiah Raghavendra et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Designing multi-targeted agents: An emerging anticancer drug discovery paradigm

(2017) Rong-geng Fu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

(2016) A.J. van der -->Wekken et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

(2016) Hai-Tao Qin et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

(2016) Elisabeth Hessmann et al.   GUT

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

(2016) Nadège Kindt et al.   Oncology Letters

HDACs and HDAC Inhibitors in Cancer Development and Therapy

(2016) Yixuan Li et al.   Cold Spring Harbor Perspectives in Medicine

Macrophage Migration Inhibitory Factor Limits Activation-Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling

(2014) Madhumita Chatterjee et al.   CIRCULATION RESEARCH

Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis

(2013) Yubiao Guo et al.   Cancer Cell International

Shifting from the single to the multitarget paradigm in drug discovery

(2013) José L. Medina-Franco et al.   DRUG DISCOVERY TODAY

Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases

(2013) Frank J. Dekker et al.   DRUG DISCOVERY TODAY

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

(2012) Geneviève P Delcuve et al.   Clinical Epigenetics

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)

(2009) S. E. Witta et al.   ANNALS OF ONCOLOGY

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

(2007) David J. Witter et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS